赵晓莹,张文,尹海庆,胡健,王辰辰,朱晓东,郭伟剑,陈治宇

• 1:复旦大学附属肿瘤医院肿瘤内科
• 2:复旦大学上海医学院肿瘤学系
• 3:河南宏力医院肿瘤内科
• 4:解放军第455医院消化内科

摘要(Abstract)：

目的探讨FOLFIRI方案联合或不联合贝伐珠单抗治疗转移性胃肠胰神经内分泌癌(gastroenteropancreatic neuroendocrine carcinoma,GEP-NEC)的疗效和安全性。方法回顾性分析12例转移性GEP-NEC患者临床资料,采用FOLFIRI方案(伊立替康+亚叶酸钙+5-氟尿嘧啶)联合或不联合贝伐珠单抗治疗,收集疗效和不良反应相关数据。结果 12例患者中,6例(50.0%)为既往EP方案(依托泊苷+顺铂)治疗失败,2例(16.7%)为其他方案(1例吉西他滨+白蛋白紫杉醇,1例奥沙利铂+卡培他滨)治疗失败,另4例为一线治疗。12例疾病控制率为83.3%(10/12),其中7例(58.3%)为部分缓解(partial response,PR),3例(25.0%)为疾病稳定(stable disease,SD),2例(16.7%)为疾病进展(progressive disease,PD)。7例(58.3%)联合贝伐珠单抗治疗,其中4例(57.1%)PR,2例(28.6%)SD,1例(14.3%)PD。5例不联合贝伐珠单抗患者,其中3例(60.0%)PR,1例(20.0%)SD,1例(20.0%)PD。所有患者无进展生存时间为5.1月(3.8-6.4月)。Ⅲ~Ⅳ度毒性反应发生率为25.0%(3/12),且均为Ⅲ度粒细胞减少,其他的常见不良反应包括贫血、转氨酶升高、高血压和蛋白尿等,均为Ⅰ~Ⅱ度。结论FOLFIRI方案联合或不联合贝伐珠单抗在转移性GEP-NEC患者中的缓解率良好且耐受性佳。

关键词(KeyWords)： 胃肠肿瘤/药物疗法;胰腺肿瘤/药物疗法;癌,神经内分泌/药物疗法;抗肿瘤联合化疗方案/治疗应用;顺铂/治疗应用;依托泊甙/治疗应用;抗体,单克隆/治疗应用;血管生成抑制剂/治疗应用;治疗结果;安全;回顾性研究

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 赵晓莹,张文,尹海庆,胡健,王辰辰,朱晓东,郭伟剑,陈治宇

DOI: 10.13267/j.cnki.syzlzz.2016.05.016

参考文献(References)：

• [1]Yao JC,Hassan M,Phan A,et al.One hundred years after"carcinoid":epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States[J].J Clin Oncol,2008,26(18):3063-3072.
• [2]Lepage C,Ciccolallo L,De Angelis R,et al.European disparities in malignant digestive endocrine tumours survival[J].Int J Cancer,2010,126(12):2928-2934.
• [3]Sorbye H,Welin S,Langer SW,et al.Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma(WHO G3):the NORDIC NEC study[J].Ann Oncol,2013,24(1):152-160.
• [4]Brenner B,Tang LH,Klimstra DS,et al.Small-cell carcinomas of the gastrointestinal tract:a review[J].J Clin Oncol,2004,22(13):2730-2739.
• [5]Sorbye H,Strosberg J,Baudin E,et al.Gastroenteropancreatic high-grade neuroendocrine carcinoma[J].Cancer,2014,120(18):2814-2823.
• [6]Yamaguchi T,Machida N,Morizane C,et al.Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system[J].Cancer Sci,2014,105(9):1176-1181.
• [7]张晓琛,徐农.肺神经内分泌肿瘤的诊治[J].实用肿瘤杂志,2014,29(5):412-416.
• [8]Noda K,Nishiwaki Y,Kawahara M,et al.Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer[J].N Engl J Med,2002,346(2):85-91.
• [9]Yamaguchi T,Machida N,Morizane C,et al.Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system[J].Cancer Sci,2014,105:1176-1181.
• [10]Hentic O,Hammel P,Couvelard A,et al.FOLFIRI regimen:an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3[J].Endocr Relat Cancer,2012,19(6):751-757.
• [11]Garcia-Carbonero R,Sorbye H,Baudin E,et al.ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas[J].Neuroendocrinology,2016,103(2):186-194.
• [12]Terris B,Scoazec JY,Rubbia L,et al.Expression of vascular endothelial growth factor in digestive neuroendocrine tumours[J].Histopathology,1998,32(2):133-138.
• [13]Raymond E,Dahan L,Raoul JL,et al.Sunitinib malate for the treatment of pancreatic neuroendocrine tumors[J].N Engl J Med,2011,364(6):501-513.
• [14]Kunz PL,Balise RR,Fehrenbacher L,et al.Oxaliplatinfluoropyrimidine chemotherapy plus bevacizumab in advanced neuroendocrine tumors:an analysis of 2 phaseⅡtrials[J].Pancreas,2016,[Epub ahead of print].
• [15]Klppel G.Classification and pathology of gastroenteropancreatic endocrine neoplasms[J].Endocr Relat Cancer,2011,18(Suppl 1):S1-16.
• [16]中国胃肠胰神经内分泌肿瘤病理专家组.中国胃肠胰神经内分泌肿瘤病理学诊断共识[J].中华病理学杂志,2011,40(4):257-262.
• [17]Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours-revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
• [18]Cancer Therapy Evaluation Program.Common terminology criteria for adverse events v4.03.2010[EB/OL].(2010-06-14)[2016-08-10].http://101.96.10.64/evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
• [19]Janson ET,Sorbye H,Welin S,et al.Nordic guidelines2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms[J].Acta Oncol,2014,53(10):1284-1297.
• [20]Moertel CG,Kvols LK,O'Connell MJ,et al.Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin.Evidence of major therapeutic activity in the anaplastic variants of these neoplasms[J].Cancer,1991,68(2):227-232.
• [21]Welin S,Sorbye H,Sebjornsen S,et al.Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy[J].Cancer,2011,117(20):4617-4622.
• [22]Saltz LB,Clarke S,Diaz-Rubio E,et al.Bevacizumab in combination with oxaliplatin-based chemotherapy as firstline therapy in metastatic colorectal cancer:a randomized phaseⅢstudy[J].J Clin Oncol,2008,26(12):2013-2019.
• [23]van Adrichem RC,Kamp K,van Deurzen CH,et al.Is there an additional value of using somatostatin receptor subtype 2a immunohistochemistry compared to somatostatin receptor scintigraphy uptake in predicting gastroenteropancreatic neuroendocrine tumor response?[J].Neuroendocrinology,2016,103(5):560-566.
• [24]Tournigand C,Andre T,Achille E,et al.FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:a randomized GERCOR study[J].J Clin Oncol,2004,22(2):229-237.
• [25]Van Cutsem E,Cervantes A,Adam R,et al.ESMO consensus guidelines for the management of patients with metastatic colorectal cancer[J].Ann Oncol,2016,27(8):1386-1422.